{
  "id": "insilico-medicine-nominates-ai-powered-ism0676-after-preclinical-weight-loss-success",
  "title": "Insilico Medicine nominates AI-powered ISM0676 after preclinical weight-loss success",
  "summary": "Insilico Medicine, a generative artificial intelligence-driven clinical-stage biotechnology company, announced the nomination of ISM0676, an AI-designed, orally available glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, as a preclinical candidate for obesity and related metabolic disorders, the company said. ISM0676 was nominated 14 months after project initiation using fewer than 200 synthesized molecules guided by Insilico’s Chemistry42 […] The post Insilico Medicine nominates AI-powered ISM0676 after preclinical weight-loss success appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/insilico-medicine-nominates-ai-powered-ism0676-after-preclinical-weight-loss-success/",
  "source": "Longevity.Technology",
  "author": null,
  "category": "news",
  "publishedAt": "2026-01-30T11:36:08.000Z",
  "fetchedAt": "2026-02-04T10:49:05.819Z",
  "relevanceScore": 0.4,
  "matchedKeywords": [
    "longevity",
    "peptide"
  ],
  "relatedProducts": [],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.867Z"
}